GlassScriptPhysician profile
Ronald James Bates
NPI 1477540532
$6,544.28
in general payments reported to CMS, 2019-2025
36 companies · $945 in 2025
The $945 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $674 · 2021: $1,039 · 2022: $1,232 · 2023: $791 · 2024: $1,028 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,763.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,169.08 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $965.61 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $809.97 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $468.78 | 2019-2025 | |
| Glaxosmithkline, LLC. | $371.02 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $362.56 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $355.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $347.08 | 2019-2023 | Verquvo, Steglujan, Belsomra |
| Abbvie INC. | $217.34 | 2021-2025 | Vraylar |
| Abbott Laboratories | $199.21 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $146.84 | 2020-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.38 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $112.18 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $102.35 | 2020-2022 | |
| Esperion Therapeutics, INC. | $82.48 | 2020-2024 | Nexletol |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $77.65 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $57.65 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.16 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $55.05 | 2021 | |
| Shockwave Medical, INC | $52.27 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Kowa Pharmaceuticals America, INC. | $50.33 | 2025 | Zoryve |
| Impel Pharmaceuticals INC. | $48.62 | 2022 | |
| Lundbeck LLC | $35.18 | 2022-2023 | Vyepti |
| Genentech USA, INC. | $32.67 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $30.93 | 2024-2025 | Voquezna |
| Dexcom, INC. | $30.25 | 2021-2022 | |
| Eisai INC. | $28.71 | 2020 | |
| Almatica Pharma LLC | $24.36 | 2022 | |
| Arbor Pharmaceuticals, INC. | $23.08 | 2020-2021 | |
| Exact Sciences Corporation | $17.75 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $16.76 | 2022 | |
| Shire North American Group INC | $16.25 | 2019 | |
| Allergan, INC. | $13.63 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.22 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $13.04 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.